Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia
Elias J Jabbour, Hagop Kantarjian, Lina Eliasson, A Megan Cornelison, David Marin, Elias J Jabbour, Hagop Kantarjian, Lina Eliasson, A Megan Cornelison, David Marin
Abstract
Dramatically improved survival associated with tyrosine kinase inhibitor (TKI) therapy has transformed the disease model for chronic myeloid leukemia (CML) to one of long-term management, but treatment success is challenged with poor medication adherence. Many risk factors associated with poor adherence can be ameliorated by close monitoring, dose modification, and supportive care. Controlling risk factors for poor adherence in combination with patient education that includes direct communication between the health care team and the patient are essential components for maximizing the benefits of TKI therapy.
Copyright © 2012 Wiley Periodicals, Inc.
Source: PubMed